Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma.

about

Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma.

Item

http://www.wikidata.org/entity/Q55033721

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Toxic epidermal necrolysis (TE ...... (PD-1 inhibitor) for lymphoma.

@en

type

Item

label

Toxic epidermal necrolysis (TE ...... (PD-1 inhibitor) for lymphoma.

@en

prefLabel

Toxic epidermal necrolysis (TE ...... (PD-1 inhibitor) for lymphoma.

@en

P1476

Toxic epidermal necrolysis (TE ...... (PD-1 inhibitor) for lymphoma

@en

P2093

Hana Alachkar

http://www.w3.org/2001/XMLSchema#string

Kim M Linton

http://www.w3.org/2001/XMLSchema#string

Laura Cove-Smith

http://www.w3.org/2001/XMLSchema#string

Liezel L Griffin

http://www.w3.org/2001/XMLSchema#string

Rebecca Brooke

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016.

Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy.

Toxic Epidermal Necrolysis-like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma.

Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.

P304

229-231

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1016/J.JDCR.2017.09.028

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

John Radford

P577

2018-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29687056

http://www.w3.org/2001/XMLSchema#string

P932

5909477

http://www.w3.org/2001/XMLSchema#string